Epidemiologia y Prevencion del Cancer en Cataluña, 1972–1992

Borràs, J M; Vilaidu, P.; Bosch, Fèlix; Borrell, Carme

doi:10.1016/s0213-9111(98)76461-1

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Spain, ovarian cancer has an annual incidence of 7.9 per 100 000 women, and an annual death rate of 3.7 per 100 000 women (Borrás et al, 1997). Due to the often asymptomatic nature of the early stages of disease, many cases of ovarian cancer have a very poor diagnosis and are not detected until the advanced stages, which suggest that a low survival rate since 5-year survival rates for women in advanced stages of the disease are only around 30% (Gore, 1999, pp 76 -90).…”

mentioning

confidence: 99%

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

Ojeda

Sande²,

Casado

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

The study consisted of a cost-minimisation analysis since the findings from a multicentre randomised phase III trial showed that pegylated liposomal doxorubicin hydrochloride was at least as efficacious as topotecan. An economic model from the Spanish hospitals perspective was constructed to compare the costs derived from the treatment using both drugs in patients with recurrent epithelial ovarian cancer who failed a first-line platinum-containing regimen. The cost evaluation included direct medical costs: drug, drug administration and costs of managing adverse events. Estimation of resources used in managing adverse events was made retrospectively through an expert panel. Results obtained per patient were: cost of drug and administration, 8647.70 euros for pegylated liposomal doxorubicin hydrochloride and 8519.94 euros for topotecan, while cost of managing adverse events was 967.02 euros in the pegylated liposomal doxorubicin hydrochloride arm and 3304.75 euros for topotecan. The total cost per patient was therefore estimated to be 9614.72 euros for pegylated liposomal doxorubicin hydrochloride and 11 824.69 euros for topotecan, showing that pegylated liposomal doxorubicin hydrochloride produces a cost saving of 2209.97 euros per patient in comparison to topotecan. Sensitivity analyses verified the robustness of the results. These findings suggest that pegylated liposomal doxorubicin hydrochloride is an efficient therapy and can be used as a cost-saving option for treatment of patients with recurrent epithelial ovarian cancer who have failed a first-line platinum-containing regimen.

show abstract

mentioning

confidence: 99%

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

Ojeda

Sande²,

Casado

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…La incidencia mundial del cáncer de cuello es de alrededor 440.000 casos por año, habiéndose observado, en la última década, un ligero incremento de la incidencia y de la mortalidad del cáncer de cérvix en algunos países desarrollados 1 . En España ocupa el tercer lugar (8,5 casos por 100.000 mujeres/año), en orden de incidencia, detrás del cáncer de endometrio y del de ovario 2 .…”

Section: Discussionunclassified

Cáncer de cérvix: análisis de 72 casos

et al. 2005

View full text Add to dashboard Cite

show abstract

“…25 The data presented are also helpful in explaining why the incidence of, and mortality from, smoking-related cancers only recently began to increase among women. [26][27][28][29] Our results allow us to predict that in the years to come, we will observe an increase in tobaccorelated diseases among women.…”

Section: Discussionmentioning

confidence: 99%

Pattern of smoking initiation in Catalonia, Spain, from 1948 to 1992

Borràs¹,

Fernández²,

Schiaffino³

et al. 2000

Am J Public Health

View full text Add to dashboard Cite

OBJECTIVES: This study analyzed the pattern of smoking initiation by sex and educational level in Catalonia, Spain. METHODS: Data from the 1994 Catalan Health Interview Survey were used (n = 12,245). The age and smoking status of each subject were reconstructed for each calendar period. Age-specific smoking initiation rates were calculated. RESULTS: Smoking initiation among females was rare until the 1960s, but from the period 1968-1972 onward a converging pattern was observed between the genders. Women with higher levels of education started smoking before other women, but the gradient of educational level has changed in recent years, with higher initiation rates among less-educated women. CONCLUSIONS: These results are consistent with diffusion-of-innovations theory and could be related to social and economic changes from the 1960s onward in Spain.

show abstract

Epidemiologia y Prevencion del Cancer en Cataluña, 1972–1992

Cited by 3 publications

References 0 publications

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

Cáncer de cérvix: análisis de 72 casos

Pattern of smoking initiation in Catalonia, Spain, from 1948 to 1992

Contact Info

Product

Resources

About